2024 - Mastering the Art of Developing a Successful Bispecific Antibody
Date2024-09-10
Deadline2024-09-10
VenueONLINE-VIRTUAL, USA - United States
KeywordsLife Sciences; Pharmaceutical; Drug Discovery & Development
Topics/Call fo Papers
Transitioning from single-functional antibodies to sophisticated bispecific designs introduces unique challenges. Unlike traditional antibodies, bispecifics require tailored screening strategies to identify the most effective format.
Join us to gain valuable insights into the strategies and methodologies that can help you navigate the complexities of bispecific antibody development.
In this webinar, we will explore the principles and practices of developing successful bispecific antibodies. We will delve into intelligent bispecific design, focusing on key factors such as avidity, spacing and the formatting of fragment antigen binding (Fab) and single-chain fragment vehicle (scFv) arms. Our approach aims to streamline the screening process, allowing for broad exploration with minimal designs.
Keywords: Antibodies, Drug Development, Clinical Research, CRO, Monoclonal Antibodies, Antibody Drug, Monoclonal Antibody, Cell & Gene Therapy, Bispecific Antibody
Join us to gain valuable insights into the strategies and methodologies that can help you navigate the complexities of bispecific antibody development.
In this webinar, we will explore the principles and practices of developing successful bispecific antibodies. We will delve into intelligent bispecific design, focusing on key factors such as avidity, spacing and the formatting of fragment antigen binding (Fab) and single-chain fragment vehicle (scFv) arms. Our approach aims to streamline the screening process, allowing for broad exploration with minimal designs.
Keywords: Antibodies, Drug Development, Clinical Research, CRO, Monoclonal Antibodies, Antibody Drug, Monoclonal Antibody, Cell & Gene Therapy, Bispecific Antibody
Other CFPs
- Why Authenticity and Patient Voice Are Critical When Driving Clinical Trial Diversity
- Strategic Advantages of Early-Phase Oncology Clinical Development Across Australia and the USA
- Enabling Clinical Programs Through Antibody Glycosylation
- Sarcopenia: Changes and Challenges in Body Composition with GLP-1 Receptor Agonist-based Weight Loss Therapies
- Advancing Precision Oncology: Radionuclide Conjugate and Antibody-Drug Conjugate (ADC) Development Strategies
Last modified: 2024-08-09 03:22:34